Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Liquid Formulation of ROTAVIN

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy infants as established by medical history and clinical examination before entering the study.~2. Age: 60-91 days (both days inclusive) at the time of enrollment.~3. Parental/legally acceptable representative ability and willingness to provide written informed consent.~4. Parent/legally acceptable representative who intends to remain in the area with the child during the study period.~Exclusion Criteria:~1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment (temporary exclusion).~2. Presence of fever on the day of enrollment (temporary exclusion).~3. Acute disease at the time of enrollment (temporary exclusion).~4. Concurrent participation in another clinical trial at any point throughout the entire time frame for this study.~5. Presence of significant malnutrition (weight-for-height z-score \< -3 SD median)~6. Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrine, immunological, dermatological, neurological, cancer, or autoimmune disease) as determined by medical history and / or physical examination which would compromise the participant's health or is likely to result in nonconformance to the protocol.~7. History of congenital abdominal disorders, intussusception, or abdominal surgery.~8. Known or suspected impairment of immunological function based on medical history and physical examination.~9. Household contact with an immunosuppressed individual or pregnant woman.~10. Prior receipt of rotavirus or an intent to receive this vaccine from outside of the study center during study participation.~11. Prior receipt of Expanded Program on Immunization (EPI) vaccination during past 7 days or plan to receive them within next 7 days.~12. A known sensitivity or allergy to any components of the study vaccine.~13. History of allergy to antibiotic kanamycin.~14. Clinically detectable significant congenital or genetic defect.~15. History of persistent diarrhea (defined as diarrhea that lasts 14 days or longer).~16. Receipt of immunoglobulin therapy and / or blood products since birth or planned administration during the study period.~17. History of chronic administration (defined as more than 14 days) of immunosuppressants including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study.~18. Any medical condition in the parent/legally acceptable representative or infant which, in the judgment of the Investigator, would interfere with or serves as a contraindication to protocol adherence.

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 91 Days
- Healthy Volunteers: t

Study Arms:
- ROTAVIN Liquid Formulation (Type: EXPERIMENTAL): Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.
- ROTAVIN-M1 Frozen Formulation (Type: ACTIVE_COMPARATOR): Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete